問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Dermatology

Division of Others-Immunodermatology, Adverse drug reactions, Drug hypersensitivity, Pharmacogenomics

Division of General Internal Medicine

Taipei Chang Gung Medical Foundation (在職)

Division of Dermatology

Division of Others-Immunodermatology, Adverse drug reactions, Drug hypersensitivity, Pharmacogenomicspsoriasis,

Chang Gung Medical Foundation Chang Gung Memorial Hospital, Keelung

Division of Dermatology

更新時間：2023-10-24

鐘文宏Chung, Wen-Hung
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

  • chung1@cgmh.org.tw

Recruiting Trial

46Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

鐘文宏

List

77Cases

2019-11-13 - 2021-03-18

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response or are Intolerant to Biologic DMARD Therapy

  • Condition/Disease

    Active Psoriatic Arthritis

  • Test Drug

    Filgotinib

Participate Sites
6Sites

Terminated6Sites

2022-01-01 - 2023-12-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2020-07-01 - 2023-06-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2021-09-01 - 2023-07-31

Phase II

Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritus in Subjects with Prurigo Nodularis

  • Condition/Disease

    Prurigo Nodularis/Pruritis

  • Test Drug

    KPL-716/ vixarelimab

Participate Sites
4Sites

Recruiting4Sites

2023-01-19 - 2026-01-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2023-01-27 - 2025-09-30

Phase III

A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

  • Condition/Disease

    Atopic Dermatitis

  • Test Drug

    Rocatinlimab (AMG 451)

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting2Sites

Terminated1Sites

2010-01-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2019-07-10 - 2020-02-12

Phase II

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Assess the Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

  • Condition/Disease

    Atopic Dermatitis

  • Test Drug

    REGN3500 and REGN668 (Dupilumab)

Participate Sites
4Sites

Terminated4Sites

2018-03-01 - 2021-06-30

Phase III

A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis

  • Condition/Disease

    Atopic Dermatitis

  • Test Drug

    Baricitinib (LY3009104)

Participate Sites
6Sites

Terminated6Sites

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2017-11-01 - 2019-12-31

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

  • Condition/Disease

    Moderate to Severe Atopic Dermatitis

  • Test Drug

    Baricitinib (LY3009104)

Participate Sites
6Sites

Terminated6Sites

李婉若
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

1 4 5 6 7 8
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB